Vaginal active agent delivery procedures and formulations thereof
First Claim
Patent Images
1. An intra-vaginal composition for intra vaginal administration into a mammal, said composition being or having, as a solids admixture, an active principle in admixture with γ
- -cyclodextrin and/or hydroxypropyl β
-cyclodextrin.
2 Assignments
0 Petitions
Accused Products
Abstract
Intra-vaginal delivery procedures including compositions and units therefor whereby an effective releasable amount of oestradiol 17β is released to achieve an efficacious effect insofar as oestrus expression is concerned. Preferably a cyclodextrin is utilized to enhance absorption.
-
Citations
23 Claims
-
1. An intra-vaginal composition for intra vaginal administration into a mammal, said composition being or having, as a solids admixture, an active principle in admixture with γ
- -cyclodextrin and/or hydroxypropyl β
-cyclodextrin. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 15)
- -cyclodextrin and/or hydroxypropyl β
-
11. In a mammalian herd oestrus synchrony procedure which involves the insertion into and the subsequent withdrawal from each mammal of the herd of an intra vaginal device adapted to deliver progesterone, the use of an oestradiol co-treatment which involves a timely intra vaginal insertion into each such mammal of an intra vaginal dosage form having an active principal selected from the group consisting of (i) oestradiol benzoate, (ii) oestradiol 17β
- , (iii) prodrugs of (i) and, (iv) prodrugs of (ii) in admixture with a cyclodextrin selected from the group consisting of γ
-cyclodextrin and hydroxypropyl β
-cyclodextrin. - View Dependent Claims (13, 14, 16, 17, 19, 20)
- , (iii) prodrugs of (i) and, (iv) prodrugs of (ii) in admixture with a cyclodextrin selected from the group consisting of γ
-
12. In a mammalian oestrus expression procedure which involves the insertion into and the subsequent withdrawal from each mammal of the herd of an intra vaginal device adapted to deliver progesterone, the use of an oestradiol co-treatment which involves a timely intra vaginal insertion into each such mammal of an intra vaginal dosage form having an active principal selected from the group consisting of (i) oestradiol benzoate, (ii) oestradiol 17β
- , (iii) prodrugs of (i) and, (iv) prodrugs of (ii) in admixture with a cyclodextrin selected from the group consisting of γ
-cyclodextrin and hydroxypropyl β
-cyclodextrin.
- , (iii) prodrugs of (i) and, (iv) prodrugs of (ii) in admixture with a cyclodextrin selected from the group consisting of γ
-
18. An intra vaginal tablet or capsule formed of or having from 0.72 to 7.2 mg of oestradiol 17β
- in admixture with a cyclodextrin selected from one or both of γ
-cyclodextrin and/or hydroxypropyl β
-cyclodextrin, the mole ratio of the cyclodextrin(s) to oestradiol ranging from 0.5;
1 to 1.5;
1.
- in admixture with a cyclodextrin selected from one or both of γ
-
21. An intra vaginal table or capsule formed or having an analogue of oestradiol 17β
- in an amount equivalent to 0.72 to 7.2 mg of oestradiol 17β and
from 6 to 150 mg cyclodextrin(s). - View Dependent Claims (22, 23)
- in an amount equivalent to 0.72 to 7.2 mg of oestradiol 17β and
Specification